Psychiatry & Neurology Doctors in Crown Point, IN Accepting Medicare

7 Psychiatry & Neurology doctors found. Showing 1 - 7

Cheng Du, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 12750 St Francis Dr, Crown Point, IN 46307 Phone: 219-757-6121    Fax: 219-681-6897

Ashish Jain, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 2050 N Main St Ste C, Crown Point, IN 46307 Phone: 219-662-3300    Fax: 219-662-3301

Olaniyi Oladotun Osuntokun, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 2100 N Main St Ste 304, Crown Point, IN 46307 Phone: 574-546-1900    Fax: 574-546-1999

Lynnea Carder, MD Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 2100 N Main St # 304, Crown Point, IN 46307 Phone: 574-546-1900    Fax: 574-546-1999

Dr. Aisha Hasan Shareef, M.D. Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 5521 W Lincoln Hwy, Crown Point, IN 46307 Phone: 219-750-9665    Fax: 219-750-9672

Dr. Kim Bolan Simic, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 12750 Saint Francis Dr, Crown Point, IN 46307 Phone: 219-852-1524    Fax: 219-933-2288

Dr. Fadel Shaaban, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 12750 Saint Francis Dr, Crown Point, IN 46307 Phone: 219-852-1524    Fax: 219-933-2288

News Archive

The most effective anti-smoking ads scare or disgust

According to researchers in the United States, in order for anti-smoking adverts to be effective they must either scare or disgust the audience.

Anti-TNFs, methotrexate may reduce risk of cardiovascular disease in people with RA

Taking methotrexate or anti-TNFs is associated with a reduction in risk of cardiovascular disease in people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

Positive results from Alkermes' ALKS 5461 phase 1/2 study on MDD

Alkermes plc today presented positive results from the phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression, in an oral session at the 52nd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting in Phoenix.

GeoVax Labs postpones proposed public offering

GeoVax Labs, Inc., a biotechnology company dedicated to developing vaccines that prevent and fight human immunodeficiency virus (HIV), today announced that it has decided to postpone its proposed public offering of units, each consisting of a share of common stock and a warrant to purchase another share.

Read more Medical News

› Verified 2 days ago